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Background: Predictors of left ventricular reverse remodeling (LVRR) after therapy with angiotensin converting
enzyme inhibitors or angiotensin-receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
(IDC) remains unclear.
Methods: We studied 44 patients with IDC who had been treated with the therapy. LVRR was defined as LV
end-diastolic dimension≤ 55 mm and fractional shortening≥ 25% at the last echocardiogram.
Results: During a mean follow-up period of 4.7 ± 3.3 years, LVRR occurred in 34% (15/44) of the patients. We
divided the patients into 2 groups: (1) patients with LVRR (n = 15); (2) patients without LVRR (n = 29). The presence
of atrial fibrillation was 40% in patients with LVRR and 14% in those without (p = 0.067). Initial LV end-diastolic
dimension was significantly smaller (62 ± 6 vs. 67 ± 6 mm, p = 0.033) in patients with LVRR than in those without.
Initial LV end-diastolic dimension of 63.5 mm was an optimal cutoff value for predicting LVRR (sensitivity: 67%,
specificity: 59%, area under the curve: 0.70, p = 0.030). When patients were further allocated according to initial
LV end-diastolic dimension≤ 63.5 mm with atrial fibrillation, the combined parameter was a significant predictor
of LVRR by univariate logistic regression analysis (odds ratio, 5.78, p = 0.030) (sensitivity: 33%, specificity: 97%,
p = 0.013).
Conclusions: Combined information on LV end-diastolic dimension and heart rhythm at diagnosis is useful in
predicting future LVRR in patients with IDC.
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Idiopathic dilated cardiomyopathy (IDC) is characterized
by left ventricular (LV) dilatation with systolic dysfunc-
tion [1]. Reverse remodeling (RR), which is a decrease in
LV size with an improvement in systolic function, has an
important role in prognosis of IDC [2-10]. Recently, oc-
currence of LVRR during follow-up has been reported to* Correspondence: matsumur@kochi-u.ac.jp
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nosis [5,8]. Therefore, prediction of future LVRR at ini-
tial diagnosis is of prognostic significance. Nevertheless,
predictors of LVRR remain unclear in IDC [11]. The aim
of the present study was to identify predictors of LVRR
in patients with IDC after therapy with angiotensin con-
verting enzyme (ACE) inhibitors or angiotensin-receptor
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Figure 1 Occurrence of LVRR and clinical outcomes during a
follow-up period of 4.7 ± 3.3 years. LVRR, left ventricular reverse
remodeling; IDC, dilated cardiomyopathy.
Matsumura et al. Cardiovascular Ultrasound  (2015) 13:14 Page 2 of 6Methods
We retrospectively studied 44 patients with IDC who
were treated with therapy with ACE inhibitors or ARBs
and β blockers. ACE inhibitors or ARBs and β blockers
were continued during follow-up in all patients, al-
though there were some changes of the other concomi-
tant drugs, such as diuretics, when clinically indicated.
All patients were admitted to our hospital for confirm-
ation of diagnosis, risk assessment, and symptom man-
agement during the period from 1994 to 2006. The
study was approved by the Ethics Committee on Medical
Research of the Kochi Medical School. All patients gave
informed consent. On admission, an exhaustive clinical
evaluation including medical history, physical examin-
ation, 12-lead electrocardiography, ambulatory 24-hour
electrocardiography, laboratory studies, echocardiography,
and cardiac catheterization was performed, in each patient
to identify cause of cardiomyopathy as precisely as possible.
The diagnostic criteria were: (1) dilated LV end-diastolic
dimension (Dd) > 55 mm with fractional shortening
(FS) < 25%; (2) exclusion of patients with acute myocardi-
tis, infiltrative myocardial disease, connective-tissue disease,
endocrine dysfunction, neuromuscular disease, general sys-
temic disease, significant coronary artery stenosis (defined
as diameter narrowing of > 50% in any of the major coron-
ary arteries or their branches), valvular disease, sensitivity/
toxic reactions and a history of excessive alcohol intake.
LVDd, LV end-systolic dimension (Ds), thicknesses of the
interventricular septum, LV posterior wall, and left atrial
dimension were measured by M-mode echocardiography
as recommended by the American Society of Echocar-
diography [12]. LVFS was calculated as ((LVDd – LVDs)/
LVDd) × 100. Echocardiography was performed in routine
clinical practice. The study patients underwent echocardi-
ography at baseline and within 1 year of the last visit, death,
or transplantation. LV reverse remodeling (LVRR) was de-
fined as described previously (LV end-diastolic dimension
(Dd) ≤ 55 mm and fractional shortening (FS) ≥ 25% at the
last echocardiogram) [5,10]. Follow-up data were obtained
by regular visits and chart reviews, and telephone contact
with the patients or their relatives.
Statistical analysis
Categorical variables are presented as total number and
% of patients, and continuous variables are presented as
means ± standard deviation. Fisher’s exact test was used
to analyze categorical variables. Differences in continu-
ous variables were analyzed by the unpaired Student’s
t test or Mann–Whitney test, as appropriate. Receiver
operating characteristic curve analysis was used to deter-
mine the discriminating cutoff value for predicting
LVRR. Univariate logistic regression analysis was used to
determine a significant predictor of LVRR. A p value of
< 0.05 was considered statistically significant.Results
The incidence of LVRR and clinical outcomes during a
mean follow-up period of 4.7 ± 3.3 years (range 5 months
to 12 years) are shown in Figure 1. LVRR occurred in
34% (15/44) of the patients. LVRR occurred at 6 months
in 2 patients, and after 12 months in 13 patients. All pa-
tients who showed LVRR survived. Of the remaining 29
patients without LVRR, 8 patients died (heart failure
death in 5 patients, sudden cardiac death in 3), 1 under-
went heart transplantation, and 20 survived. The inci-
dence of cardiac death and heart transplantation was
significantly higher in patients without LVRR than in
those without (p = 0.018).
We divided the patients into 2 groups: (1) patients
with LVRR, (2) patients without LVRR. There were no
significant differences in the frequency of use of ACE in-
hibitors or ARBs. We most frequently used enalapril
(83%) (30/36) as an ACE inhibitor and losartan (63%) (5/
8) as an ARBs. There were no significant differences in
these maintenance doses between the 2 groups. Carve-
dilol was administered in 37 patients and metoprolol in
7 patients. There were no significant differences in the
frequency of use of these drugs. There were no signifi-
cant differences in these maintenance doses between the
2 groups (Table 1).
Atrial fibrillation was found in 40% (6/15) of patients
with LVRR, and in 14% (4/29) of those without LVRR
(p = 0.067). The initial heart rate was 87 ± 21 (60–105)
beats/min in 6 patients with LVRR, and that was 98 ± 28
(80–140) beats/min in 4 patients without LVRR. No dif-
ference was found in the initial heart rate between the 2
groups (P = 0.390). The heart rate was > 100 beats/min
Table 1 Initial clinical characteristics
Variables LVRR (+) LVRR (−) p value
(n = 15) (n = 29)
Age (years) 60 ± 11 58 ± 13 0.512
Men 13 (87%) 26 (89%) 0.767
New York Heart Association class
I – II 11 24 0.207
III – IV 5 5
Diabetes mellitus 4 (27%) 3 (10%) 0.206
Atrial fibrillation 6 (40%) 4 (14%) 0.067
Nonsustained ventricular tachycardia 6 (40%) 11 (38%) 0.894
Serum creatinine (mg/dl) 0.87 ± 0.16 0.81 ± 0.25 0.406
Estimated glomerular filtration rate (ml min-1 1.73 m-2) 80.3 ± 12.2 79.8 ± 12.1 0.738
Complete left bundle brunch brock 2 (13%) 6 (21%) 0.549
QRS duration (ms) 101 ± 14 111 ± 32 0.173
Follow-up periods (years) 5.9 ± 3.2 4.4 ± 2.8 0.220
Pharmacological treatments
β blockers 15 (100%) 29 (100%) >0.99
Carvedilol 13 (87%) 24 (83%) 0.737
Dose (mg/day) 11.3 ± 4.8 10.8 ± 5.3 0.761
Metoprolol 2 (13%) 5 (17%) 0.735
Dose (mg/day) 60.0 ± 28.2 56.0 ± 21.9 0.879
Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers 12 / 3 (100%) 24/5 (100%) >0.99
Enalapril 10 (67%) 20 (69%) 0.877
Dose (mg/day) 5.2 ± 1.8 4.6 ± 0.9 0.318
Losartan 2 (13%) 3 (20%) 0.767
Dose (mg/day) 37.5 ± 17.7 41.7 ± 14.4 0.738
Loop diuretics 13 (87%) 27 (93%) 0.596
Spironolactone 7 (45%) 15 (52%) 0.751
Digitalis 11 (73%)’ 20 (67%) 0.763
Amiodarone 1 (7%) 4 (14%) 0.647
Data are presented as mean ± SD or n (%). LVRR, left ventricular reverse remodeling.
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with heart rate of 105 beats/min showed LVRR, and 1
patient with heart rate of 140 beats/min did not show
LVRR. Atrial fibrillation recovered to sinus rhythm in 2
patients who did not show LVRR. Initial LVDd was
significantly smaller in patients with LVRR than in
those without LVRR (Table 2). No other differences were
found between the 2 groups. Initial and last echocardio-
graphic parameters are shown in Table 3. Initial LVDd
of 63.5 mm was an optimal cutoff value for predicting
LVRR (sensitivity: 67%, specificity: 59%, area under the
curve: 0.70, p = 0.030) by receiver operating characteristic
curve analysis. When patients were further allocated ac-
cording to initial LVDd ≤ 63.5 mm in combination with
atrial fibrillation, initial LVDd ≤ 63.5 mm with atrial fibril-
lation was a significant predictor of LVRR by univariatelogistic regression analysis (odds ratio, 5.78; 95% confi-
dence interval, 1.19 – 28.0, p = 0.030) (sensitivity: 33%,
specificity: 97%, p = 0.013).
Discussion
The present study had major 2 findings. First, initial LVDd
was significantly smaller in patients with LVRR than in
those without. Second, when patients were further allocated
according to initial LV end-diastolic dimension ≤ 63.5 mm
with atrial fibrillation, the combined parameter was a
significant predictor of LVRR by univariate logistic re-
gression analysis (odds ratio: 5.78, p = 0.030).
LVRR has a key role in favorable prognosis of IDC
[2-10]. Although many predictors of LVRR in patients
with IDC have been reported, inconsistent results exist
in the past studies [2,8,11,13-19]. This was probably
Table 2 Initial echocardiographic and cardiac catheterization findings
Variables LVRR (+) LVRR (−) p value
Left ventricular end-diastolic dimension (mm) 62 ± 6 67 ± 6 0.033
Left ventricular end-systolic dimension (mm) 53 ± 6 57 ± 8 0.093
Left ventricular fractional shortening (%) 15 ± 4 14 ± 5 0.574
Interventricular septal thickness (mm) 10 ± 2 10 ± 1 0.727
Left ventricular posterior wall thickness (mm) 10 ± 2 9 ± 2 0.165
Relative wall thickness 0.32 ± 0.01 0.29 ± 0.06 0.106
Left atrial dimension (mm) 43 ± 6 42 ± 7 0.653
Left ventricular mass index (g/m2) 204 ± 58 196 ± 68 0.703
Left ventricular end-diastolic volume index (ml/m2) 144 ± 72 169 ± 43 0.197
Left ventricular end-systolic volume index (ml/m2) 100 ± 66 119 ± 42 0.274
Left ventricular ejection fraction (%) 34 ± 13 31 ± 9 0.357
Left ventricular end-diastolic pressure (mm Hg) 12 ± 6 12 ± 7 0.819
Pulmonary capillary wedge pressure (mm Hg) 11 ± 8 11 ± 8 0.929
Systolic pulmonary artery pressure (mm Hg) 30 ± 12 29 ± 9 0.672
Mean pulmonary artery pressure (mm Hg) 19 ± 8 19 ± 9 0.961
Right ventricular end-diastolic pressure (mm Hg) 8 ± 3 7 ± 4 0.806
Mean right atrial pressure (mm Hg) 6 ± 2 6 ± 4 0.963
Systolic aortic pressure (mm Hg) 112 ± 22 112 ± 19 0.985
Mean aortic pressure (mm Hg) 87 ± 15 84 ± 12 0.614
Cardiac index (ml/min/m2) 2.1 ± 0.6 2.2 ± 0.6 0.486
Data are presented as mean ± SD. LVRR, left ventricular reverse remodeling.
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clinical factors such as pharmacological therapy. Although
the ACE inhibitors or ARBs and β blockers that block the
neurohormonal activation play an important role in indu-
cing LVRR, there is no report on prediction of LVRR after
therapy with ACE inhibitors or ARBs and β blockers in
patients with IDC. In the present study, initial LVDd was
smaller in patients with LVRR than in those without
LVRR. Initial LVDd of ≤ 63.5 mm was significantly associ-
ated with future LVRR by receiver operating characteristic
curve analysis. In a past study, myocardial recovery was
evident in 32% of the patients on a LV assist device whoTable 3 Initial and last echocardiographic findings
Variables LVRR (+)
Initial
Left ventricular end-diastolic dimension (mm) 62 ± 6
Left ventricular end-systolic dimension (mm) 53 ± 6
Left ventricular fractional shortening (%) 15 ± 4
Interventricular septal thickness (mm) 10 ± 2
Left ventricular posterior wall thickness (mm) 10 ± 2
Relative wall thickness 0.32 ± 0.01
Left atrial dimension (mm) 43 ± 6
Left ventricular mass index (g/m 2) 204 ± 58
Data are presented as mean ± SD. LVRR, left ventricular reverse remodeling.had initial LVDd < 60 mm [20]. In contrast, myocardial re-
covery was not evident in all patients who had initial
LVDd > 70 mm. More recently, in the multicenter IMAC-
2 study, LVDd at presentation predicted a better LV sys-
tolic function at 6 months [21]. The authors have stated
that smaller LV size is likely a marker of a more reversible
cardiac pathological condition. Similarly, the present study
suggests that initial LVDd could provide important infor-
mation in predicting future LVRR.
Atrial fibrillation is a common arrhythmia in patients
with IDC. The presence of atrial fibrillation tended to
be associated with LVRR in the present study. WhenLVRR (−)
Last Initial Last
49 ± 4 67 ± 6 62 ± 9
33 ± 4 57 ± 8 50 ± 11
32 ± 4 14 ± 5 20 ± 8
10 ± 1 10 ± 1 10 ± 1
10 ± 1 9 ± 2 9 ± 1
0.41 ± 0.06 0.29 ± 0.06 0.30 ± 0.08
42 ± 6 42 ± 7 41 ± 7
140 ± 30 196 ± 68 176 ± 54
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LVDd ≤ 63.5 mm with concomitant atrial fibrillation, this
combined parameter was a significant predictor of LVRR
by univariate logistic regression analysis. The parameter
of initial LVDd ≤ 63.5 mm with concomitant atrial fibril-
lation had high specificity and low sensitivity. These
results suggest that the combined parameter is useful
for predicting future LVRR, but not useful for denying
future LVRR.
It is problematic to determine whether atrial fibrillation
is the primary cause of the cardiomyopathy (tachycardia-
induced cardiomyopathy), or secondary to IDC [22,23].
We are still in this old dilemma of “which came first”:
chicken, or egg [24]? Tachycardia-induced cardiomyop-
athy is retrospectively diagnosed by marked improvement
in LV function typically seen in 4 – 6 weeks [23].
Prolonged heart rate > 100 beats/min has been reported to
be also important in its diagnosis [23]. However, there
are no absolute parameters which distinguish between
tachycardia-induced cardiomyopathy and IDC. In the
present study, the patients with atrial fibrillation had
not typical feature of tachycardia-induced cardiomyop-
athy in view of the initial heart rate and time of appear-
ance of LVRR. Also, no significant difference was found
in initial LVDd between patients with atrial fibrillation
and those without (data not shown). Although these re-
sults indicate that patients of the present study with atrial
fibrillation had IDC but not tachycardia-induced cardio-
myopathy, initial LV end-diastolic dimension ≤ 63.5 mm
with atrial fibrillation was a significant predictor of LVRR,
suggesting that atrial fibrillation might be associated with
future LVRR.
The targeting doses of ACE inhibitors, ARBs, and β
blockers were lower in the present study than those in
the United States’ guidelines [25]. A low dose of carve-
dilol of 5 mg/day was beneficial in Japanese patients with
heart failure in the Multicenter Carvedilol Heart Failure
Dose Assessment (MUCHA) trial [26]. We have previ-
ously reported that low doses of ACE inhibitors, ARBs,
and β blockers had favorable effects on the prognosis of
Japanese patients with IDC [27,28]. The Japanese Guide-
lines (available at the Japanese Circulation Society Web
site (http://www.j-circ.or.jp/) have recommended a tar-
geting dose of enalapril of 5 to 10 mg/day and of carve-
dilol of 5 to 20 mg/day.
The present study has several limitations as follows:
(1) The study was retrospective, and the number of pa-
tients was small; (2) Although all patients showed basic-
ally diffuse LV wall motion abnormalities, calculated
LVFS would not be a representative estimate of systolic
function, particularly when regional abnormalities were
present; (3) Because these limitations could affect the
results of the present study, care should be taken when
applying the results to the individual patients; (4) Thereare no currently available parameters that can accurately
distinguish between tachycardia-induced cardiomyop-
athy and IDC; (5) Further studies especially with a large
number of patients are required to confirm the results of
the present study.
Conclusions
Initial LVDd was significantly smaller in patients with
LVRR than in those without. Initial LVDd ≤ 63.5 mm in
combination with atrial fibrillation was a significant pre-
dictor of future LVRR. Combined information on LVDd
and heart rhythm at diagnosis is useful in predicting fu-
ture LVRR in patients with IDC.
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